Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Ontology highlight
ABSTRACT: Oncogenic fusion events have been identified in a broad range of tumors. Among them, RET rearrangements represent distinct and potentially druggable targets that are recurrently found in lung adenocarcinomas. We provide further evidence that current anti-RET drugs may not be potent enough to induce durable responses in such tumors. We report that potent inhibitors, such as AD80 or ponatinib, that stably bind in the DFG-out conformation of RET may overcome these limitations and selectively kill RET-rearranged tumors. Using chemical genomics in conjunction with phosphoproteomic analyses in RET-rearranged cells, we identify the CCDC6-RETI788N mutation and drug-induced mitogen-activated protein kinase pathway reactivation as possible mechanisms by which tumors m
SUBMITTER: Plenker D
PROVIDER: S-EPMC5805089 | biostudies-literature | 2017 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA